Apologies in advance for the long post... click Next if you

New Post Public Reply Private Reply Replies (2) Message Board
Warp Daveludlow #6219
Apologies in advance for the long post... click Next if you don't want to waste the next 2 minutes of your life. LOL

Dave, the dilution concern you continue to refer to as legitimate is obviously not shared by the majority on this board. We are not the naive investors as you think we are. But your concerns over this issue are starting to sound like the rants of those who believe the moon landings were faked, and are frustrated they can't convince everyone else of the truth of this. Seriously, you need to get a grip. Take your concerns to the company, or sell your shares. Most of the naive investors here understand the dilution concern yet we choose to remain invested and keep our focus on the company and the bright outlook of our future.

So your 1.1 million shares represent hard earned money, do they? What the hell do my shares represent? You have no f*cking idea what you're talking about when you make any attempt to characterize me or my investment style. I take my concerns to the source, not to a public message board where others can do little to nothing about it. Gerald has personally addressed every one of my concerns, and in some cases stated the company would be addressing those concerns in the near future, which they have. I'm satisfied with that. If that's a passive investor, then I suppose I choose to remain a passive investor vs. claiming to be a LT investor yet fretting and losing sleep over every possible outcome in my investment. I feel management has enough challenges ahead of them without me creating more by constantly reminding them of my own insecurities with my investment decision. As Gerald has stated, they are building a world-class biotech company, and if I can't stand the heat of the kitchen, then I should sell my shares and move on. Good advice, in my opinion.

It is not the CEO's job to manage my investment as you claim. It is management's job to manage the company and bring shareholder value, using their knowledge and experience to manage the science and build the best shareholder value they can based on bringing their assets to market. It is my job to manage my investment. It is my job to decide to stick with this investment or not based on my results and how I view the company being managed. It is not my job to try to manage the company, nor attempt to sway investor sentiment to agree with my opinion and put pressure on management to better manage my investment. They are busy running the company. If I had the qualifications to manage the company, I'd be working for them, not simply buying their shares.

You seem to believe I'm wealthy. Again, your analysis here sucks. What is your definition of wealth? And how do you think I came into the money to buy my large position? I'll tell you how. I worked my ass off for years, working 12-hour rotating shifts, and adding 600+ hours annually of overtime for many years. While others were taking off to spend time with family and friends on weekends and holidays, I was at the nuclear plant working. So I would characterize my investment dollars just as hard earned, if not more so, than those you've put into your investment. So how about less talk of your hard-earned dollars? Most here earned the money they invest. Your dollars are no different than anyone else's here.

I can assure you of this... if I only owned 100K or 500K in AMBS shares, my concern over possible dilution ahead would be no different than it is now. I live in reality, not the fantasy world you suggest. The real world would have investors who wouldn't invest in pre-revenue biotech companies if they were concerned about dilution. In the fantasy world, investors invest in such companies often to counter their life-long tendency to borrow for everything, not save enough for retirement, and pin all of their hopes on striking it rich, which is why they fret over everything that "might" happen with their investment, instead of having more trust in management to do what is best both for shareholders and the company.

Let me tell you how I view God in this environment. I pray for Gerald and his team, and those conducting the research to help those in need. I pray that this investment will work out the way God intends, whatever that may be. And I pray God has my best interests in mind, whether that is to provide me with abundant wealth to help others in need, or to teach me a valuable lesson about what many would consider my foolish investment of my limited resources in a risky company like Amarantus.

So, while you are fretting and flipping out over what might happen, I have faith this will all work out as God intended. Gerald is not God. But I believe he is genuinely a good person and may very well be one of God's instruments to help those suffering from these various afflictions. And if I'm blessed to enjoy some rewards as a shareholder, I will certainly do my part in passing on some of those blessings to others in need, as well as my local church to spread God's ministry. If you think that's a "passive" investor, so be it. I imagine my blood pressure and sleep patterns are a lot better than yours. And my faith this will all work according to God's plan gives me comfort. That doesn't mean I don't bring my concerns to the company. One would be a fool to blindly invest and hope it all works out, but we obviously have different levels of faith in this investment.

I'd rather drink Kool-Aid than whatever brew you're drinking. What I'm drinking isn't causing unnecessary concerns over what might happen down the road. You really should watch a specific episode of Deep Space Nine called "Statistical Probabilities" (season 6, episode 9). It is a prime example of your over-analysis of everything Amarantus, and how a single event can change everything and make all of the analysis moot.

Speaking of maturity, it seems to me most here are calm adults who understand the risks. But some seem to be spoiled brats crying for attention and pissed off that everyone else doesn't share their concerns.

One final point... you should work on your reading skills because your mention of my post regarding one of the callers on the recent business update call is way off.

What you posted:
Quote:
Unlike Warp, I thought the gentleman who pressed Gerald on those 5 questions during the CC was right on!! Warp writes off discussion about concerns as anxious "hand wringing" and the cause of "sleepless nights" that only the poor engage in, who really shouldn't be invested in this type of stock in the first place. I thought the gentleman asking the questions on the CC was respectful, but earnest.
What I posted:
Quote:
I sat here listening to these 5 questions and was scratching my head, particularly the ones asking Gerald to reveal any partnerships or asset sales in the works, and when the company expected to be profitable. It's sad this investor took up so much time on the call where other investors could have asked reasonable questions that Gerald might be able to legally answer.

So you believe a reasonable investor question would be for specifics on upcoming sales of the LymPro and Eltoprazine assets, or when the company will reach profitability based on partnership agreements or asset sales currently in the works? You really see those questions as respectful and ernest? What fantasy world are you living in? There's no way Gerald could answer those questions, and not wind up with SEC fines or removal by the BOD as CEO. Respectful and ernest? What kind of shareholder would even ask those questions? One who is out of his league as an investor here and should stick with investing in mutual funds. I'm surprised you feel these were valid questions that should be asked.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 6

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 10

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 4

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 6

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 9

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Market Sentiment Towards Exxon Mobil Corp Explained

Updated Category News Views 208

Understanding Market Sentiment for Exxon Mobil Corp Exxon Mobil Corp (NYSE:XOM) has recently witnessed a notable increase in its short interest as a percentage of float, which has surged by 3.37%. Current data indicates that there are approximately 39.97 million shares sold short, translating to 0.92% of all regular shares available for trading. With this trading volume,...

Continue Reading
2026 Beach Destinations Highlight Tourism Goldmine

Updated Category News Views 17

Fresh Findings on Coveted Coastal Spots Here we are again with Travel And Tour World (TTW) rolling out their prized list of beachy paradises fit for 2026. They’ve done their homework and uncovered some of the finest spots our planet's surf and sand have to offer. This year, it's about much more than just pretty shores; it's an ode to pristine ecosystems and vibrant...

Continue Reading
FEMSA's Strong Forward Momentum in Third Quarter 2024

Updated Category News Views 344

Overview of FEMSA's Third Quarter 2024 Performance Fomento Económico Mexicano, S.A.B. de C.V. (NYSE: FMX) has recently shared its operational and financial results for the third quarter of 2024. The results display solid growth across various facets of the business, signaling resilience amidst a challenging economic landscape. Consolidated Revenue Growth The consolidated...

Continue Reading
Electro-Sensors, Inc. Reports Impressive Q3 Financial Results

Updated Category News Views 157

Electro-Sensors, Inc. Financial Results for Q3 Electro-Sensors, Inc. (NASDAQ: ELSE), a prominent provider of machine monitoring sensors and hazard detection systems, reported impressive financial results for the third quarter. The company experienced a quarterly revenue of $2,512,000, marking a significant increase of 22.1% compared to the same period last year. Growth in...

Continue Reading
Global Net Lease, Inc. Reveals Details on Preferred Dividends

Updated Category News Views 162

Global Net Lease, Inc. Reveals Preferred Stock Dividend Information Global Net Lease, Inc. (NYSE: GNL) has officially announced the declaration of quarterly dividends on its preferred stocks. This is a key development for the company as it continues to focus on providing value to its shareholders. The declared dividends are: Details of the Dividends The first dividend is...

Continue Reading